Recruiting Pulmonary Embolism Studies in Stanford
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study...
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on my...
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Wheth...
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH ...
Automated Insulin Delivery for Inpatients With Dysglycemia
This randomized controlled trial will test the efficacy and safety of automated insulin delivery (AID) in hospitalized patients with diabetes (type 1 or type 2) requiring insulin therapy who are admit...
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
The purpose of the research is to determine whether parent-mediated behavior therapy for challenging behavior commonly displayed by children with autism spectrum disorder (ASD) can be as effective whe...
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multipl...
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspecte...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...
About Pulmonary Embolism Clinical Trials in Stanford
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 9 pulmonary embolism clinical trials recruiting participants in Stanford, CA. These studies are seeking a combined 1,233 participants. Research is being sponsored by GB002, Inc., Dennis M. McNamara, MD, MS, Alessandro Doria and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Stanford — FAQ
Are there pulmonary embolism clinical trials in Stanford?
Yes, there are 9 pulmonary embolism clinical trials currently recruiting in Stanford, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Stanford?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Stanford research site will contact you about next steps.
Are clinical trials in Stanford free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Stanford studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 9 active trials in Stanford are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov